Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia.

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout Ardea Biosciences, Inc . announced that additional positive scientific and preclinical results from its development system of lesinurad, the Organization's lead product candidate for the treating hyperuricemia and gout, were presented in the Annual European Congress of Rheumatology hosted by the European Group Against Rheumatism in London, UK. Outcomes from Major Dosing Period and Ongoing Extension of Phase 2b Combination Study with Allopurinol Outcomes shown from the ongoing blinded extension portion of Ardea's Phase 2b study of lesinurad in patients who did not achieve target on allopurinol therapy alone demonstrated that for those patients who have reached week 28 of the extension period, 91 % of those patients receiving lesinurad in conjunction with allopurinol achieved serum urate levels below the clinically important focus on of 6 mg/dL.

A standard abdominal discomfort responder was defined as a patient who experienced at least a thirty % decrease in abdominal discomfort from baseline for 6 of 12 weeks. The overall responder rate, or dual composite endpoint %, was achieved in 50.0 % of patients receiving tenapanor 50 mg daily versus 23 twice.6 % receiving placebo . A standard responder was thought as a patient who was both an overall CSBM responder and a standard abdominal pain responder in the same week for 6 of 12 weeks. As shown in the table, various other key secondary endpoints that exhibited significant improvements for sufferers receiving 50 mg tenapanor twice daily compared to placebo-treated individuals included abdominal discomfort, abdominal bloating, straining, stool regularity, CSBM per week and SBM weekly.